SOAT1 and diffuse large B-cell lymphoma: Their stratification separates the GCB-DLBCL class into two major subtypes: SHM1, characterized by a high frequency of not always concurrent BCL2 and MYC aberrations and mutations in chromatin modifying genes, and including cases with poor outcome after standard R-CHOP therapy, that could be directed to alternative therapies; and SHM3, featuring mutations in the JAK-STAT pathway and a better outcome to standard cure.